Genotyping NAT2 with only two SNPs (rs1041983 and rs1801280) outperforms the tagging SNP rs1495741 and is equivalent to the conventional 7-SNP NAT2 genotype

Genotyping N-acetyltransferase 2 (NAT2) is of high relevance for individualized dosing of antituberculosis drugs and bladder cancer epidemiology. In this study we compared a recently published tagging single nucleotide polymorphism (SNP) (rs1495741) to the conventional 7-SNP genotype (G191A, C282T, T341C, C481T, G590A, A803G and G857A haplotype pairs) and systematically analysed if novel SNP combinations outperform the latter. For this purpose, we studied 3177 individuals by PCR and phenotyped 344 individuals by the caffeine test. Although the tagSNP and the 7-SNP genotype showed a high degree of correlation (R=0.933, P<0.0001) the 7-SNP genotype nevertheless outperformed the tagging SNP with respect to specificity (1.0 vs. 0.9444, P=0.0065). Considering all possible SNP combinations in a receiver operating characteristic analysis we identified a 2-SNP genotype (C282T, T341C) that outperformed the tagging SNP and was equivalent to the 7-SNP genotype. The 2-SNP genotype predicted the correct phenotype with a sensitivity of 0.8643 and a specificity of 1.0. In addition, it predicted the 7-SNP genotype with sensitivity and specificity of 0.9993 and 0.9880, respectively. The prediction of the NAT2 genotype by the 2-SNP genotype performed similar in populations of Caucasian, Venezuelan and Pakistani background. A 2-SNP genotype predicts NAT2 phenotypes with similar sensitivity and specificity as the conventional 7-SNP genotype. This procedure represents a facilitation in individualized dosing of NAT2 substrates without losing sensitivity or specificity.

[1]  N. Malats,et al.  A single nucleotide polymorphism tags variation in the arylamine N-acetyltransferase 2 phenotype in populations of European background , 2010, Pharmacogenetics and genomics.

[2]  William Wheeler,et al.  A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci , 2010, Nature Genetics.

[3]  T. Gumbo,et al.  Treatment of Active Pulmonary Tuberculosis in Adults: Current Standards and Recent Advances , 2009, Pharmacotherapy.

[4]  J. Agúndez Polymorphisms of human N-acetyltransferases and cancer risk. , 2008, Current drug metabolism.

[5]  D. Grant Structures of human arylamine N-acetyltransferases. , 2008, Current drug metabolism.

[6]  S. Selinski,et al.  Re-investigation of the concordance of human NAT2 phenotypes and genotypes , 2005, Archives of Toxicology.

[7]  K. Golka,et al.  The enhanced bladder cancer susceptibility of NAT2 slow acetylators towards aromatic amines: a review considering ethnic differences. , 2002, Toxicology letters.

[8]  J. Benítez,et al.  Identification and prevalence study of 17 allelic variants of the human NAT2 gene in a white population. , 1996, Pharmacogenetics.

[9]  J. Brockmöller,et al.  Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. , 1995, American journal of human genetics.

[10]  B. Korf,et al.  Preliminary phenotypic map of chromosome 4p16 based on 4p deletions. , 1995, American journal of medical genetics.

[11]  L. H. Schmidt,et al.  Metabolism of isoniazid in man as related to the occurrence of peripheral neuritis. , 1954, American review of tuberculosis.